These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9488096)

  • 1. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
    Filiadis IF; Georgiou IA; Giannakopoulos X
    Br J Urol; 1998 Feb; 81(2):342-3. PubMed ID: 9488096
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
    Espin Jaime MT; Moran Penco JM; Garcia Agundez JA; Caballero Loscos MJ; Sanjuan Rodriguez S; Botello Martinez F; Gomez de Tbjada R; Laguna Alvarez E; Benitez Rodriguez I
    Br J Urol; 1997 Jul; 80(1):151-2. PubMed ID: 9240200
    [No Abstract]   [Full Text] [Related]  

  • 3. [The acetylator phenotype in patients with urinary bladder cancer].
    Wich H; Franke G; Grimm U; Siegmund W
    Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Axonal neuropathy and salazosulfapyridine: slow-acetylator phenotype].
    Blin O; Sangla I; Jouglard J; Cottin C; Pellissier JF; Serratrice G
    Rev Neurol (Paris); 1992; 148(2):154-6. PubMed ID: 1351312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overrepresentation of the slow acetylator phenotype in painters suffering from urinary bladder cancer.
    Golka K; Kempkes M; Flieger A; Blaszkewicz M; Bolt HM
    Med Lav; 1997; 88(5):425-6. PubMed ID: 9489306
    [No Abstract]   [Full Text] [Related]  

  • 9. Acetylator phenotype in human bladder cancer.
    Miller ME; Cosgriff JM
    J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2'-dimethyl-4-aminobiphenyl.
    Jiang W; Feng Y; Hein DW
    Toxicol Appl Pharmacol; 1999 May; 156(3):187-94. PubMed ID: 10222311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
    Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
    Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
    Hanke J; Krajewska B
    Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
    Schröder H; Evans DA
    Gut; 1972 Apr; 13(4):278-84. PubMed ID: 4402420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphasalazine induced agranulocytosis.
    Hutchinson D; Wyld PJ
    N Z Med J; 1983 Jul; 96(735):520-1. PubMed ID: 6137796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study.
    Filiadis IF; Georgiou I; Alamanos Y; Kranas V; Giannakopoulos X; Lolis D
    J Urol; 1999 May; 161(5):1672-5. PubMed ID: 10210437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonitis induced by sulphasalazine.
    Peters FP; Engels LG; Moers AM
    Postgrad Med J; 1997 Feb; 73(856):99-100. PubMed ID: 9122107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylator status, drug metabolism and disease.
    Pande JN; Pande A; Singh SP
    Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylator phenotype in bladder cancer.
    Miller ME
    Lancet; 1982 Dec; 2(8311):1348. PubMed ID: 6128635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.